SCHEMBL1982164

SCHEMBL1982164

CCC(=C(C#N)C#N)c1cccc(OC)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.50
CES1 P23141 1/20 0.50
PDE4A P27815 3/20 0.48
PDE4B Q07343 3/20 0.48
PDE4C Q08493 3/20 0.48
PDE4D Q08499 3/20 0.48
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
PARP1 P09874 1/20 0.47
PRSS1 P07477 1/20 0.47
PRSS2 P07478 1/20 0.47
PRSS3 P35030 1/20 0.47
ALDH1A1 P00352 2/20 0.47
MAPT P10636 1/20 0.47
PKM P14618 1/20 0.47
XBP1 P17861 1/20 0.47
MAPK1 P28482 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
NR1I2 O75469 1/20 0.44
TAS1R3 Q7RTX0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2634455 0.86 NPC1 (0.50) CES2CES1PDE4APDE4BPDE4C
SCHEMBL2634453 0.86 NPC1 (0.50) CES2CES1PDE4APDE4BPDE4C
SCHEMBL16244739 0.86 NPC1 (0.50) CES2CES1PDE4APDE4BPDE4C
SCHEMBL1983099 0.83 CES2 (0.46) CES2CES1PDE4APDE4BPDE4C
SCHEMBL18636170 0.81 NPC1 (0.56) CES2CES1NPC1RAB9APARP1
SCHEMBL21378219 0.81 NR1I2 (0.69) CES2CES1PDE4APDE4BPDE4C
SCHEMBL12960155 0.80 HPGD (0.44) PARP1ALDH1A1MAPTTAS1R3TAS1R1
SCHEMBL9688906 0.80 CES2 (0.53) CES2CES1PDE4APDE4BPDE4C
SCHEMBL12463281 0.79 NPC1 (0.53) CES2CES1NPC1RAB9APARP1
SCHEMBL1982248 0.78 NPC1 (0.56) CES2CES1PDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2512242-B1 NOVEL COMPOUNDS GLAXOSMITHKLINE IP DEV LTD (GB) 2015-09-30 EP disclosed
EP-2512242-B1 NOVEL COMPOUNDS GLAXOSMITHKLINE IP DEV LTD (GB) 2015-09-30 EP disclosed
US-9029545-B2 Thienopyridine NOX2 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) 2015-05-12 US disclosed
US-9029545-B2 Thienopyridine NOX2 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) 2015-05-12 US disclosed
EP-2512242-A1 NOVEL COMPOUNDS Glaxo Wellcome Manufacturing Pte Ltd (SG) 2012-10-24 EP disclosed
US-20120252805-A1 NOVEL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) 2012-10-04 US disclosed
US-20120252805-A1 NOVEL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) 2012-10-04 US disclosed
WO-2011075559-A1 NOVEL COMPOUNDS GLAXO WELLCOME MANUFACTURING PTE LTD. (SG) 2011-06-23 WO disclosed
WO-2011075559-A1 NOVEL COMPOUNDS GLAXO WELLCOME MANUFACTURING PTE LTD. (SG) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252805-A1 NOVEL COMPOUNDS CYBB, NOX1, NOX4 CES2 806/4885CES1 742/4885PDE4A 345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.